← Leaderboards
Fang-Tsyr Lin
Baylor College Of Medicine
$3,618,481
Attributed
$5,810,866
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $748.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,810,866 · 4
By mechanism
R01$5,408,303 · 3
R21$402,563 · 1
Top collaborators
- Weei-Chin Lin12 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Weei-Chin Lin$10,211,771
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoNew Therapeutic TargetNovel TherapeuticsResponseBindingMalignant Breast NeoplasmMalignant NeoplasmsTranslatingProteinsOverexpressionMediatingPreventXenograft ProcedureTumorResistanceRegulationMutantLeadDrug ResistanceApoptosisFunctional DisorderDna BiosynthesisCancer Therapy
Grant awards (19)
Novel therapeutics for targeting checkpoint dysfunction in cancer$382,469
R01 · FY2025 · CA
14-3-3tau drives estrogen receptor loss and breast cancer progression$366,000
R01 · FY2025 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer$363,346
R01 · FY2024 · CA
14-3-3tau drives estrogen receptor loss and breast cancer progression$347,701
R01 · FY2024 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer$374,819
R01 · FY2023 · CA
14-3-3tau drives estrogen receptor loss and breast cancer progression$366,000
R01 · FY2023 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer$382,469
R01 · FY2022 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer$362,569
R01 · FY2021 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer$362,569
R01 · FY2020 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer$351,691
R01 · FY2019 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer$362,569
R01 · FY2018 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer$362,569
R01 · FY2017 · CA
Role of TRIP6 in Malignant Glioma Progression$121,248
R21 · FY2010 · NS · contact PI
Role of TRIP6 in Malignant Glioma Progression$61,877
R21 · FY2010 · NS · contact PI
Role of TRIP6 in Malignant Glioma Progression$219,438
R21 · FY2009 · NS · contact PI
Lysophosphatidic Acid Signaling in Ovarian Cancer$252,035
R01 · FY2006 · CA · contact PI
Lysophosphatidic Acid Signaling in Ovarian Cancer$258,100
R01 · FY2005 · CA
Lysophosphatidic Acid Signaling in Ovarian Cancer$258,100
R01 · FY2004 · CA
Lysophosphatidic Acid Signaling in Ovarian Cancer$255,297
R01 · FY2003 · CA